The week in pharma: action, reaction and insight – week to November 29

By Barbara Obstoj-Cardwell. Editor

Among important regulatory news last week, US drugmaker BridgeBio Pharma gained Food and Drug Administration (FDA) approval for its cardiomyopathy drug Attruby (acoramidis). On the research front, Biohaven posted disappointing data for its spinal muscular atrophy (SMA) and obesity candidate taldefgrobep. Also, PTC Therapeutics released new Phase II data on its investigational amyotrophic lateral sclerosis drug utreloxastat that missed its goal. Also of note, Arrowhead Pharmaceutical entered into an agreement, potentially worth $11 billion, granting rights to Sarepta Therapeutics for a multiple clinical program in the area of muscle, CNS and lung disease.

BridgeBio: Worth the wait – Attruby approved in ATTR-CM